Published in Pancreas on August 01, 2010
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer (2012) 1.30
Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol (2014) 1.17
A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol (2014) 1.09
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) (2015) 0.98
A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer (2013) 0.97
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci (2014) 0.95
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol (2012) 0.92
¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One (2013) 0.90
Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme. Medicine (Baltimore) (2015) 0.89
Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search. World J Gastroenterol (2012) 0.87
Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report. Am J Case Rep (2016) 0.85
Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification. Int Surg (2013) 0.85
Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol (2013) 0.84
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist (2016) 0.84
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol (2015) 0.82
Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother (2013) 0.81
Large cell neuroendocrine - Adenocarcinona mixed tumour of colon: Collision tumour with peculiar behaviour. What do we know about these tumours? Ann Med Surg (Lond) (2015) 0.80
Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors (2013) 0.80
Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. J Cancer (2014) 0.79
A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy. Case Rep Oncol (2011) 0.78
Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors. Medicine (Baltimore) (2016) 0.77
Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review. BMC Cancer (2014) 0.77
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer (2016) 0.75
Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon. J Gastrointest Oncol (2016) 0.75
CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET. Medicine (Baltimore) (2016) 0.75
Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med (2016) 0.75
Carcinoma-like nonfunctional pheochromocytoma in the right adrenal gland: A case report. Oncol Lett (2016) 0.75
Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms. Transl Gastroenterol Hepatol (2016) 0.75
Report of two cases of large cell neuroendocrine carcinoma of duodenal ampulla with contrasting outcomes following pancreaticoduodenectomy according to the use of adjuvant chemotherapy. Int J Surg Case Rep (2017) 0.75
Neuroendocrine Cancer of Rectum Metastasizing to Ovary. Case Rep Oncol Med (2016) 0.75
Small Cell Ovarian Carcinomas - Characterisation of Two Rare Tumor Entities. Geburtshilfe Frauenheilkd (2013) 0.75
Large cell neuroendocrine cervical tumor treated by radical surgery and adjuvant chemotherapy: A case report and literature review. Oncol Lett (2015) 0.75
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors. J Clin Oncol (2013) 0.75
Mixed Adenoneuroendocrine Carcinoma Is a Rare but Important Tumour Found in the Oesophagus. Case Rep Gastrointest Med (2016) 0.75
A case of definitive therapy for localised prostate cancer: report of a urological nightmare. Adv Urol (2011) 0.75
A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature. Case Rep Oncol (2016) 0.75
Mixed large cell neuroendocrine carcinoma with squamous cell carcinoma of the rectum: Report of a rare case and review of the literature. Int J Surg Case Rep (2013) 0.75
Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues. Medicine (Baltimore) (2015) 0.75
Primary high-grade neuroendocrine carcinoma of the heart. Tex Heart Inst J (2013) 0.75
Pancreatic body adenocarcinoma with neuroendocrine tumor characteristics: A case report. Oncol Lett (2014) 0.75
Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci (2017) 0.75
A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. J Cancer Res Clin Oncol (2015) 0.75
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia (2017) 0.75
Poorly-differentiated colorectal neuroendocrine tumour: CT differentiation from well-differentiated neuroendocrine tumour and poorly-differentiated adenocarcinomas. Eur Radiol (2017) 0.75
Mixed adenoneuroendocrine carcinoma derived from the cystic duct: A case report. Int J Surg Case Rep (2017) 0.75
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer (1991) 2.98
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol (2006) 2.91
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol (2002) 2.89
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer (1997) 2.11
Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch (1995) 1.91
Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev (2008) 1.83
Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer (2004) 1.75
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol (2008) 1.54
Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cancer (2007) 1.48
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2001) 1.44
Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol (2009) 1.35
Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg (1996) 1.26
Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol (1996) 0.97
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol (2007) 8.29
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 6.10
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol (2013) 5.07
The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas (2010) 5.01
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol (2008) 4.45
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med (2008) 3.08
Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol (2004) 3.08
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril (2002) 2.48
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer (2009) 2.38
Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Retracted MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem (2010) 2.34
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg (2005) 2.19
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol (2004) 2.18
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A (2007) 2.17
Results after pancreatic resection for metastatic lesions. Ann Surg Oncol (2002) 2.15
Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol (2004) 2.14
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas (2010) 2.13
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res (2005) 2.13
Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol (2005) 2.12
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res (2011) 2.00
Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem (2008) 1.98
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology (2012) 1.94
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A (2008) 1.92
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas (2010) 1.90
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol (2005) 1.84
Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol (2007) 1.84
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 1.83
Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol (2012) 1.83
Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer (2002) 1.82
Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology (2008) 1.81
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol (2002) 1.79
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol (2002) 1.78
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med (2005) 1.78
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther (2005) 1.75
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol (2011) 1.75
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol (2003) 1.72
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol (2012) 1.71
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene (2005) 1.70
The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol (2002) 1.68
A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist (2005) 1.68
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol (2005) 1.67
Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg (2002) 1.66
Antiprimer quenching-based real-time PCR and its application to the analysis of clinical cancer samples. Clin Chem (2006) 1.66
Management of primary liver sarcomas. Cancer (2007) 1.65
Lymphoepithelial cysts of the pancreas: a report of 12 cases and a review of the literature. Mod Pathol (2002) 1.65
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol (2006) 1.64
Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer (2002) 1.64
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol (2007) 1.64
EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer (2012) 1.63
Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity. Virchows Arch (2006) 1.62
Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer (2013) 1.62
Combined classical carcinoid and goblet cell carcinoid tumor: a new morphologic variant of carcinoid tumor of the appendix. Am J Surg Pathol (2010) 1.61
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol (2006) 1.60
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med (2002) 1.60
Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomarkers Prev (2010) 1.60
Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol (2004) 1.58